Lyell Immunopharma reported cash from operations of -$33.92M and free cash flow of -$34.18M for the quarter ended Jun 2026, up 1.6% year over year. This cash flow statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||
| Net Income | -48.89M | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M | |||||
| Share-based Compensation | 13.04M | 21.18M | 22.03M | 22.41M | 19.12M | 18.36M | 13.88M | 14.22M | 10.52M | 8.46M | 9.15M | 8.28M | 7.62M | 8.08M | 6.02M | 5.00M | 5.23M | 25.57M | 4.29M | 4.53M | |||||
| Gains from Sales and Divestitures | -0.21M | -0.67M | -0.08M | -0.01M | -0.01M | -0.43M | -0.64M | -0.44M | -0.01M | -0.40M | -0.92M | -1.29M | -2.47M | 0.25M | 0.17M | -0.12M | |||||||||
| Asset Writedowns and Impairment | 36.40M | 5.00M | -5.00M | 51.30M | 1.44M | ||||||||||||||||||||
| Cash from Operations | -25.49M | -33.21M | -47.85M | -44.33M | -37.10M | -40.27M | -46.21M | -39.16M | -37.69M | -40.63M | -42.02M | -38.09M | -35.04M | -47.24M | -54.74M | -34.46M | -28.58M | -32.25M | -38.51M | -33.92M | |||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 4.09M | 4.57M | 4.19M | 4.17M | 4.62M | 5.04M | 5.03M | 5.06M | 5.10M | 5.06M | 5.02M | 4.90M | 4.68M | 5.03M | 3.44M | 3.13M | 2.57M | 2.40M | 2.33M | 2.22M | |||||
| Change in Working Capital | |||||||||||||||||||||||||
| Change in Account Payables | -0.99M | 0.10M | 2.94M | -1.77M | 0.02M | -0.53M | 2.07M | 0.38M | -1.41M | 0.42M | -0.11M | -0.52M | -0.57M | -2.04M | -1.65M | -0.23M | -0.78M | 0.33M | 2.38M | -1.46M | |||||
| Change in Accured Expenses | 1.94M | 4.22M | -6.39M | -0.77M | 1.32M | 5.37M | -5.86M | 2.27M | 4.61M | -1.74M | -3.61M | 0.52M | 3.09M | -1.25M | -9.79M | -3.33M | 0.57M | 4.90M | -3.57M | 4.61M | |||||
| Other Working Capital Changes | 5.18M | 2.73M | 2.13M | -38.44M | 0.00M | -48.35M | 0.41M | -1.05M | 0.30M | -2.79M | -0.59M | 0.84M | 1.61M | -3.64M | -2.00M | -2.80M | -0.42M | 2.39M | -0.09M | -3.23M | |||||
| Investing Activities | |||||||||||||||||||||||||
| Capital Expenditures | 11.60M | 10.27M | 9.73M | 7.17M | 2.79M | 4.58M | 1.53M | 0.93M | 0.20M | 0.03M | 0.03M | 0.33M | 0.06M | 0.04M | 0.25M | 0.17M | 0.06M | 0.30M | 0.09M | 0.26M | |||||
| Sales of Property, Plant and Equipment | 0.26M | 0.02M | |||||||||||||||||||||||
| Cash from Investing Activities | -144.91M | -73.86M | -26.12M | 25.02M | -57.09M | 46.65M | 32.15M | 152.91M | 99.67M | -100.69M | 21.99M | 45.01M | 1.92M | 53.51M | 69.47M | 12.65M | 3.35M | -31.36M | 17.38M | 15.62M | |||||
| Financing Activities | |||||||||||||||||||||||||
| Other financing activities | 0.37M | 0.09M | 0.07M | 0.05M | 0.21M | 0.12M | 0.08M | ||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||
| Net Equity Issued and Repurchased | -1.06M | 2.56M | 1.57M | 5.13M | 0.33M | 1.16M | 0.73M | 0.10M | 0.71M | 0.44M | 0.18M | 49.82M | 0.03M | 0.50M | |||||||||||
| Misc. | |||||||||||||||||||||||||
| Cash from Financing Activities | -0.53M | 7.40M | 2.56M | 2.46M | 4.76M | 0.86M | -0.07M | 1.20M | -0.14M | 0.76M | 0.03M | 0.86M | 0.44M | 0.00M | 0.18M | 50.00M | 0.22M | 51.72M | 0.52M | ||||||
| Change in Cash | -170.94M | -99.68M | -71.42M | -16.86M | -89.43M | 7.24M | -14.13M | 114.95M | 61.84M | -140.57M | -20.00M | 7.78M | -33.12M | 6.70M | 14.73M | -21.63M | 24.77M | -63.39M | 30.59M | -17.78M | |||||
| Free Cash Flow | -37.09M | -43.48M | -57.59M | -51.50M | -39.89M | -44.85M | -47.74M | -40.09M | -37.88M | -40.66M | -42.05M | -38.42M | -35.10M | -47.29M | -54.98M | -34.63M | -28.64M | -32.55M | -38.60M | -34.18M | |||||
| Net Cash Flow | -170.94M | -99.68M | -71.42M | -16.86M | -89.43M | 7.24M | -14.13M | 114.95M | 61.84M | -140.57M | -20.00M | 7.78M | -33.12M | 6.70M | 14.73M | -21.63M | 24.77M | -63.39M | 30.59M | -17.78M |
Pull Lyell Immunopharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=LYEL&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "LYEL", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=LYEL&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();